Synthetic antibody formulation infliximab may be an effective component of a drug regimen for patients with inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis. While a number of past reports claimed the drug to be ineffective, a recent study revisited infliximab and found it may work best after a "drug holiday."
Dr. Filip Baert, a gastroenterologist in the University Hospitals Leuven in Belgium and lead author of the study, said that infliximab proved to be highly beneficial in patients that were on other treatments. The favorable response to the drug was particularly evident in patients who were taken off infliximab, but did not find relief with subsequent alternatives. The study is currently available in Clinical Gastroenterology and Hepatology of the American Gastroenterological Association, entitled, "Decreased mucosal lymphocyte proliferation following treatment with infliximab in Crohn's disease."
Infliximab is widely known as the first anti-tumor necrosis factor (TNF) in